Eris Lifesciences acquires trademark Zomelis from Novartis AG for $13 mn - (Business Standard via NewsPoints Desk)

  • Eris Lifesciences said it has acquired the trademark "Zomelis" for vildagliptin-based formulations, and its associated trademarks, from Novartis for a consideration of $13 million, reported Business Standard.

  • "Zomelis is a strong brand amongst the super speciality prescriptions and has been promoted for close to 10 years," said Eris Lifesciences managing director Amit Bakshi.

  • The DPP-4 inhibitor is used in the treatment of type 2 diabetes.

To read more NewsPoints articles, click here.